Michel Krempf
Centre National de la Recherche Scientifique(FR)Inserm(FR)Centre de Recherche en Nutrition Humaine Rhône-Alpes(FR)Institut du Thorax(FR)PhysioPathologie des Adaptations Nutritionnelles(FR)Nantes Université(FR)
Publications by Year
Research Areas
Lipoproteins and Cardiovascular Health, Diabetes, Cardiovascular Risks, and Lipoproteins, Diet and metabolism studies, Cancer, Lipids, and Metabolism, Diabetes Treatment and Management
Most-Cited Works
- → Mutations in PCSK9 cause autosomal dominant hypercholesterolemia(2003)2,977 cited
- → A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management(2015)2,485 cited
- → Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events(2015)2,268 cited
- → Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients(1998)1,222 cited
- → 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial(2017)824 cited
- → ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia(2015)532 cited